Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci 1991;640:263-7
Date
01/01/1991Pubmed ID
1776748DOI
10.1111/j.1749-6632.1991.tb00230.xScopus ID
2-s2.0-0026398214 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
A novel compound designated HP 128, which manifests adrenergic and cholinergic properties, was administered for 10 days to patients with Alzheimer's disease in a double-blind, placebo-controlled trial. All patients who entered the trial had previously failed to respond to a structurally related cholinesterase inhibitor without adrenergic properties (HP 029). The primary purpose of the study was to assess the safety and tolerance of HP 128. Efficacy measures were obtained to generate hypotheses for possible future studies. In the dosage range examined, HP 128 was safe and well tolerated. Effects on clinical measures of dementia severity were equivocal.
Author List
Huff FJ, Antuono P, Murphy M, Beyer J, Dobson CAuthor
Piero G. Antuono MD Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAged, 80 and over
Alzheimer Disease
Aminoacridines
Drug Evaluation
Female
Humans
Male
Middle Aged
Placebos
